Dear Doctor Letter (Rote-Hand-Brief) on EFIENT® (prasugrel): increased risk of serious bleeding
2013.12.03
Active substance: prasugrel
The company Lilly Deutschland GmbH is circulating information that patients with unstable angina pectoris (UA)/NSTEMI receiving EFIENT® prior to diagnostic coronary angiography have an increased risk of serious bleeding.
(SPC - available in German only)
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN